Amendments to the Claims

The following listing of claims will replace all prior versions and listings of claims in the application.

Listing of Claims:

1. (original) A compound having the formula I, or a pharmaceutically acceptable salt thereof,


(I)

wherein

Y is -NH-R^2 or a group of formula


,

R^1 is cycloalkyl or non-substituted alkyl,

R^2 is cycloalkyl,

R^3 is hydrogen, alkyl, halogen, hydroxy, alkoxy or amino,

or R^2R^3 is an alkylene bridging group,

R^a is hydrogen, alkyl, alkenyl, alkynyl, halogen, hydroxy, alkoxy, amino, alkylamino, alkylsulfonyloxy, cyano, carboxy, ester or amido,

R^b is hydrogen, alkyl or halogen,

or R^aR^b is carbonyl,

R^4 is hydrogen or alkyl,

R^5 is cycloalkyl, arylalkyl or heterocycle-alkyl,

or NR^4R^5 is a heterocycle, which may be substituted, containing only one heteroatom which is a nitrogen atom or containing two heteroatoms wherein one is a nitrogen atom and the other is a non-oxidized sulfur atom,

with the proviso that when Y is -NHR^2 and R^{2}R^3 is an alkylene bridging group or when Y is a group of formula



R^1 is a cycloalkyl.

2. (original) A compound according to claim 1 wherein Y is -NH-R^2.

3. (original) A compound according to claim 2 wherein
R^1 is C3-7-cycloalkyl or non-substituted alkyl,
R^2 is C3-7-cycloalkyl,
R^3 is hydrogen, C1-4-alkyl, halogen, hydroxy, alkoxy or amino,
or R^2R^3 is a C2-4-alkylene bridging group,
R^4 is hydrogen or C1-4-alkyl,
R^5 is C3-7-cycloalkyl, arylalkyl or heterocycle-alkyl,
or NR^4R^5 is a heterocycle, which may be substituted, containing only one heteroatom which is a nitrogen atom or containing two heteroatoms wherein one is a nitrogen atom and the other is a non-oxidized sulfur atom.

4. (previously presented) A compound according to claim 2 wherein R^1 is C3-4-alkyl or C3-5-cycloalkyl, preferably cyclopropyl, isopropyl, cyclobutyl, cyclopentyl, 2-methyl-cyclopropyl or cyclopropylmethyl.

5. (previously presented) A compound according to claim 2 wherein
R^2 is a C3-4-non-substituted cycloalkyl, or a cycloalkyl substituted by a C1-6-alkyl or an aryl, preferably cyclopropyl or cyclobutyl,
and/or R^3 is hydrogen, methyl, ethyl, a Cl atom, a F atom, a Br atom, amino or methoxy,
or R^2R^3 is an alkylene bridging group selected from ethylene, propylene and butylene.

6. (previously presented)A compound according to claim 2 wherein
R^4 is hydrogen or C1-4-alkyl, preferably hydrogen or methyl,
and/or R^5 is 2-(2-thienyl)ethyl, 2-furylmethyl, 2-thienylmethyl, 4-pyridinylmethyl, benzyl, 2-(methylsulfanyl)benzyl, 2,6-difluorobenzyl, 2-fluorobenzyl, 2-

nitrobenzyl, 3,5-bis(trifluoromethyl)benzyl, 3,5-difluorobenzyl, cyclohexyl, cycloheptyl, 4-methylcyclohexyl, or 2,2-diphenylethyl,

or NR^4R^5 is 1,3-thiazolidin-3-yl, 1-azepanyl, 1-azocanyl, 3,5-dimethyl-1-piperidinyl, 4-(2-methoxyphenyl)-1-piperidinyl, 4-(hydroxy(diphenyl)methyl)-1-piperidinyl, 4-(trifluoromethyl)-1-piperidinyl, 4,4-difluoro-1-piperidinyl, 4,4-dimethyl-1-piperidinyl, 4-carbamoyl-1-piperidinyl, 4-benzyl-1-piperidinyl, 4-carboxy-1-piperidinyl, 4-cyano-4-phenyl-1-piperidinyl, 4-ethoxycarbonyl-1-piperidinyl, 4-ethyl-1-piperidinyl, 4-ethyl-4-methyl-1-piperidinyl, 4-hydroxy-1-piperidinyl, 4-hydroxy-4-phenyl-1-piperidinyl, 4-hydroxymethyl-1-piperidinyl, 4-methyl-1-piperidinyl, 4-methylene-1-piperidinyl, 4-oxo-1-piperidinyl, 3,6-dihydro-1(2H)-pyridinyl, 3-azabicyclo[3.2.1]oct-3-yl, 4-thiomorpholinyl, 2-one-1-azepanyl, 3,4-dihydro-2(1H)-isoquinolinyl, 1,4-dioxa-8-azaspiro[4.5]dec-8-yl, 1,3,3-trimethyl-6-azabicyclo[3.2.1]oct-6-yl, octahydro-2(1H)-isoquinolinyl or 8-azaspiro[4.5]dec-8-yl.

7. (Currently amended) A compound selected from

6-(1-azepanyl)-N,2-dicyclopropyl-5-methyl-4-pyrimidinamine;

N,2-dicyclopropyl-6-(4,4-dimethyl-1-piperidinyl)-5-methyl-4-pyrimidin-amine;

N,2-dicyclopropyl-5-methyl-6-(4-methyl-1-piperidinyl)-4-pyrimidinamine;

6-(3-azabicyclo[3.2.1]oct-3-yl)-N,2-dicyclopropyl-5-methyl-4-pyrimidinamine;

N,2-dicyclo-propyl-5-methyl-6-(4-thiomorpholinyl)-4-pyrimidinamine; and

~~4-azepan-1-yl-2-cyclopropyl-5,6,7,8-tetrahydro-pyrido[2,3-d]pyrimidine and~~

~~4-azepan-1-yl-2-cyclopropyl-6,7,8,9-tetrahydro-pyrimido[4,5-b]azepine; or~~

pharmaceutically acceptable salts thereof.

8. (original) A compound according to claim 1 wherein Y is a group of formula

9. (original) A compound according to claim 8 wherein NR^4R^5 is a 5- to 9-membered heterocycle, which may be substituted, containing only one heteroatom which is a

nitrogen atom or containing two heteroatoms wherein one is a nitrogen atom and the other is a non-oxidized sulfur atom, preferably 1-azepanyl.

10. (original) A compound according to claim 9 wherein
R^1 is C3-7-cycloalkyl,
R^3 is hydrogen, C1-4-alkyl, halogen, hydroxy, alkoxy or amino,
R^a is hydrogen, C1-4-alkyl, C2-6-alkenyl, C2-6-alkynyl, halogen, hydroxy, alkoxy, amino, alkylamino, alkylsulfonyloxy, cyano, carboxy, ester or amido,
R^b is hydrogen, C1-4-alkyl or halogen,
or R^aR^b is carbonyl.

11. (previously presented) A compound according to claim 10 wherein R^1 is C3-4-cycloalkyl, preferably cyclopropyl.

12. (previously presented) A compound according to claims 10 wherein R^3 is hydrogen or C1-4-alkyl, preferably hydrogen or methyl.

13. (previously presented) A compound according to claim 10 wherein
R^a is hydrogen, methyl, hydroxy, methoxy, methylsulfonyloxy, a Br atom, a F atom or cyano, preferably, hydrogen, methyl, hydroxy or a F atom,
and/or R^b is hydrogen or methyl, preferably hydrogen,
or R^aR^b is carbonyl.

14. (currently amended) A compound selected from
1-(6-azetidin-1-yl-2-cyclopropyl-5-methylpyrimidin-4-yl)azepane; ~~and~~
1-[2-cyclopropyl-5-methyl-6-(3-methylazetidin-1-yl)pyrimidin-4-yl]azepane;; ~~or~~ and
pharmaceutically acceptable salts thereof.

15. (previously presented) A compound according to claim 1 as a pure enantiomer.

16. (previously presented) A pharmaceutical composition comprising an effective amount of a compound according to claim 1 in combination with a pharmaceutically acceptable diluent or carrier.

17. (original) A pharmaceutical composition according to claim 16 for administration by inhalation.

18. (canceled)19. (canceled)

20. (currently amended) A method for treating respiratory disorders in connection with Chronic Obstructive Pulmonary Disease or for treating symptoms related to chronic bronchitis, emphysema, cough, cystic fibrosis, pulmonary fibrosis, adult respiratory distress syndrome, rhinitis or asthma comprising administering a therapeutically effective amount of at least one compound according to claim 1 or a pharmaceutically acceptable salt thereof to a patient.

21. (canceled)

22. (canceled)

23. (canceled)

24. (canceled)

25. (canceled)

26. (previously presented) A pharmaceutical composition comprising an effective amount of a compound according to claim 7 in combination with a pharmaceutically acceptable diluent or carrier.

27. (previously presented) A pharmaceutical composition comprising an effective amount of a compound according to claim 14 in combination with a pharmaceutically acceptable diluent or canier.

28. (previously presented) A compound according to claim 7 as a pure enantiomer.

29. (previously presented) A compound according to claim 14 as a pure enantiomer.

30. (previously presented) A pharmaceutical composition according to claim 26 for administration by inhalation.

31. (previously presented) A pharmaceutical composition according to claim 27 for administration by inhalation.

32. (previously presented) A method for treating respiratory disorders in connection with Chronic Obstructive Pulmonary Disease or for treating symptoms related to chronic bronchitis, emphysema, cough, cystic fibrosis, pulmonary fibrosis, adult respiratory distress syndrome, rhinitis or asthma comprising administering at least one compound according to claim 7 or a pharmaceutically acceptable salt thereof to a patient.

33. (previously presented) A method for treating respiratory disorders in connection with Chronic Obstructive Pulmonary Disease or for treating symptoms related to chronic bronchitis, emphysema, cough, cystic fibrosis, pulmonary fibrosis, adult respiratory distress syndrome, rhinitis or asthma comprising administering at least one compound according to claim 14 or a pharmaceutically acceptable salt thereof to a patient.